.





PATIENT NAME : NAMRATA KUMARI	REF. DOCTO	R: SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080XA008674	AGE/SEX : 35 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : NAMRF02038880	DRAWN :
DELHÍ	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43
NEW DELHI 110030 8800465156		
Test Report Status <u>Final</u>	Results Biolog	jical Reference Interval Units

нл	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	12.2	12.0 - 15.0	g/dL
	4.65	3.8 - 4.8	mil/ul
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	4.05	3.0 - 4.0	mil/µL
WHITE BLOOD CELL (WBC) COUNT	4.62	4.0 - 10.0	thou/µL
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	176	150 - 410	thou/µL
METHOD : ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	38.3	36 - 46	%
	00 0 Jaw	02 101	fL
MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED PARAMETER	82.3 Low	83 - 101	IL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.2 Low	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN	31.8	31.5 - 34.5	g/dL
CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	4.7 Low	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	17.7		
MEAN PLATELET VOLUME (MPV)	12.1 High	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	56	40 - 80	%

WBC DIFFERENTIAL COUNT		
NEUTROPHILS	56	40 - 80
METHOD : LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CELLS I	MPEDANCE	
LYMPHOCYTES	34	20 - 40
METHOD : LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CELLS I	MPEDANCE	
MONOCYTES	8	2 - 10

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Coracalit

Dr.Pranjali Vasisht LAB HEAD

Page 1 Of 26



%

%

View Details





Biological Reference Interval



Units

PATIENT NAME : NAMRATA KUMARI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080XA008674 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NAMRF02038880 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 27/01/2024 10:18:25 DELHI ABHA NO REPORTED :28/01/2024 20:07:43 : NEW DELHI 110030 8800465156

METHOD : LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CELLS IMPEDANCE

<u>Final</u>

EOSINOPHILS	2	1 - 6	%
BASOPHILS	0	0 - 2	%
METHOD : LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CE	ELLS IMPEDANCE		
ABSOLUTE NEUTROPHIL COUNT	2.59	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	1.57	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT	0.37	0.20 - 1.00	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.09	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.6		

Results

METHOD : CALCULATED PARAMETER

Interpretation(s)

Test Report Status

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Coraralit



View Report

Page 2 Of 26

View Details



Dr.Pranjali Vasisht LAB HEAD






PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : S	ELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080XA008674	AGE/SEX : 35 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : NAMRF02038880	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 27/01/2024 10:18:25
NEW DELHI 110030	ABHA NO :	REPORTED :28/01/2024 20:07:43
8800465156		
	i	

Test	Report	Status	Final
			<u></u>

Results

Biological Reference Interval Units

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE		
ERYTHROCYTE SEDIMENTATION RATE (ESR BLOOD),EDTA		
E.S.R	19	0 - 20	mm at 1 hr
METHOD : MODIFIED WESTERGREN			
BLOOD		New distantis Adult of 7	0/
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT	A WHOLE		
HBA1C	6.6 High	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4	%
		Diabetes diagnosis: > or = Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	6.5



Diaraht

Chandni Garg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD



View Details



Patient Ref. No. 77500006207456





PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0080XA008674 PATIENT ID : NAMRF02038880 CLIENT PATIENT ID:	AGE/SEX :35 Years Female DRAWN : RECEIVED :27/01/2024 10:18:25
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :28/01/2024 20:07:43
Test Report Status Final	Results Biological	Reference Interval Units

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Deraraht

Chandni Garg

Dr.Pranjali Vasisht LAB HEAD





Page 4 Of 26

View Details



PERFORMED AT: Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST





PATIENT NAME : NAMRATA KUMARI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080XA008674 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NAMRF02038880 DRAWN ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 27/01/2024 10:18:25 DELHI ABHA NO REPORTED :28/01/2024 20:07:43 : NEW DELHI 110030 8800465156

Test Report Status Final

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ADO GROOF & RITTIFL, LDTA WHOLL DLOOD	
ABO GROUP	TYPE O
METHOD : SLIDE AGGLUTINATION	POSITIVE
KRITPE	POSITIVE
METHOD : SLIDE AGGLUTINATION	

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Deraraht

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 5 Of 26

View Details








PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR :	SELF
	ACCESSION NO : 0080XA008674 PATIENT ID : NAMRF02038880	AGE/SEX : 35 Years Female DRAWN :
DELHI	1	RECEIVED : 27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

	BIOCHEMISTRY)
MEDI WHEEL FULL BODY HEALTH CHECH	KUP BELOW 40FEMALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	112 High	74 - 106	mg/dL



METHOD : HEXOKINASE

Diaraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Gneg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Page 6 Of 26

View Report

mg/dL







PATIENT NAME : NAMRATA KUMARI	REF. DOCTO	DR: SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0080XA008674 PATIENT ID : NAMRF02038880	AGE/SEX : 35 Years Female DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43
8800465156 Test Report Status Final	Results Biolog	gical Reference Interval Units

P	PBS(POST PRANDIAL BLOOD SUGAR)		
160			
128_		135 •	
96 -			
64 -			
' j pj Bu 32 -			
월 32 -			
0			
		27-JAN-2024 14:32	
NormalRange	Date>		
ID PROFILE WITH CALCULAT			
DLESTEROL, TOTAL	141	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL I
THOD : CHOLESTEROL OXIDASE, ESTERAS	E,PEROXIDASE	27 – 240 mgn	
GLYCERIDES	93	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL I
THOD : ENZYMATIC ASSAY L CHOLESTEROL	46	< 40 Low >/=60 High	mg/dL
THOD : DIRECT MEASURE - PEG	76	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High	mg/dL
		>/= 190 Very High	

Coracalit

Chandni Gneg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

Ĥ ġ +ZQC Ċ.

DA.

Page 7 Of 26

View Details View Report








PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO: 008 PATIENT ID : NAM CLIENT PATIENT ID: ABHA NO :	BOXA008674 AGE/SEX :35 Years Female 1RF02038880 DRAWN : RECEIVED :27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43	
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE			
NON HDL CHOLESTEROL	46	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	
VERY LOW DENSITY LIPOPROTEIN	18.6	Desirable value : mg/dL 10 - 35	
METHOD : CALCULATED PARAMETER			
CHOL/HDL RATIO	3.1 Low	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	
METHOD : CALCULATED PARAMETER	1.7	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

METHOD : CALCULATED PARAMETER



Drawlit



DR.CHANDNI GARG CONSULTANT PATHOLOGIST



View Details




Page 8 Of 26








PATIENT NAME : NAMRATA KUMARI	REF. DOC	CTOR : SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080XA008674	4 AGE/SEX : 35 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : NAMRF02038880	0 DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 27/01/2024 10:18:25
NEW DELHI 110030	ABHA NO :	REPORTED :28/01/2024 20:07:43
8800465156		
(
Test Report Status <u>Final</u>	Results Bio	logical Reference Interval Units





Diaraht

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



View Details



Page 9 Of 26





PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0080XA008674 PATIENT ID : NAMRF02038880 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :35 Years Female DRAWN : RECEIVED :27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target. Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category				
Extreme risk group	A.CAD with > 1 feature of high risk group			
	B. CAD with > 1 feature of Very high risk §	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C $<$ or =		
	50 mg/dl or polyvascular disease			
Very High Risk	1. Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.		
	Familial Homozygous Hypercholesterolemi	a		
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ			
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary			
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
Moderate Risk	2 major ASCVD risk factors	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ictors		
1. Age $>$ or $=$ 45 year	is in males and $>$ or $= 55$ years in females	3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD 4. High blood pressure		4. High blood pressure		
5. Low HDL				
lower treatment goal	and statin initiation thresholds based on th	a wish astagonian propagad by I AI in 2020		

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Treatment Goals Consider Drug Therapy		herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80	
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60	
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR=100	
Moderate Risk	<100	<130	>OR=100	>OR=130	
Low Risk	<100	<130	>OR=130*	>OR=160	

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD : DIAZONIUM ION, BLANKED (ROCHE)	0.55	UPTO 1.2	mg/dL
BILIRUBIN, DIRECT	0.18	0.00 - 0.30	mg/dL
METHOD : DIAZOTIZATION BILIRUBIN, INDIRECT	0.37	0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER TOTAL PROTEIN	7.3	6.6 - 8.7	g/dL
METHOD : BIURET ALBUMIN	4.9	3.97 - 4.94	g/dL
METHOD : BROMOCRESOL GREEN	-		

Coracalit

Chandni Gneg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd.

24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Page 10 Of 26









PATIENT NAME : NAMRATA KUMARI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080XA008674 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NAMRF02038880 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 27/01/2024 10:18:25 DELHI REPORTED :28/01/2024 20:07:43 ABHA NO : NEW DELHI 110030 8800465156

Test Report Status Final Results Biological Reference Interval Units GLOBULIN 2.4 2.0 - 4.0 Neonates g/dL

		Pre Mature: 0.29 - 1.04	
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	2.0	1.0 - 2.0	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE	26	0 - 32	U/L
(AST/SGOT)			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	49 High	0 - 31	U/L
METHOD : UV WITHOUT PYRIDOXAL-5 PHOSPHATE			
ALKALINE PHOSPHATASE	138 High	35 - 105	U/L
METHOD : PNPP - AMP BUFFER			
GAMMA GLUTAMYL TRANSFERASE (GGT)	78 High	5 - 36	U/L
METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE			
LACTATE DEHYDROGENASE	181	135 - 214	U/L
METHOD : LACTATE -PYRUVATE			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	8	6 - 20	mg/dL

Diaraht

METHOD : UREASE - UV

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 11 Of 26


1







PATIENT NAME : NAMRATA KUMARI	REF. DOCTO	R: SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0080XA008674	AGE/SEX : 35 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : NAMRF02038880 CLIENT PATIENT ID:	DRAWN : RECEIVED : 27/01/2024 10:18:25
NEW DELHI 110030	ABHA NO :	REPORTED :28/01/2024 20:07:43
8800465156		
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units



Diaraht

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Gneg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



mg/dL



View Report

Page 12 Of 26







PATIENT NAME : NAMRATA KUMARI	REF. DOCTO	DR: SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0080XA008674 PATIENT ID : NAMRF02038880	AGE/SEX : 35 Years Female DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43
8800465156 Test Report Status Final	Results Biolog	gical Reference Interval Units

	CREATININE	2	
1.9 -			
1.52 -			
1.14 -			
0.76 _	0.52		
	-	0.51	
0			
24-5 ——— Biological Reference Interval: 0.50 - 0.90	EP-2022 12:02 mg/dl Date	27-JAN-2024 11:34	
BUN/CREAT RATIO		2	
BUN/CREAT RATIO METHOD : CALCULATED PARAMETER	15.69 High	5.00 - 15.00	
URIC ACID, SERUM			
URIC ACID METHOD : URICASE, COLORIMETRIC	2.6	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD : BIURET	7.3	6.6 - 8.7	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD : BROMOCRESOL GREEN	4.9	3.97 - 4.94	g/dL

GLOBULIN

Diaraht

Chandni Gneg

DR.CHANDNI GARG

CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Page 13 Of 26









PATIENT NAME : NAMRATA KUMARI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080XA008674 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NAMRF02038880 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 27/01/2024 10:18:25 DELHI REPORTED :28/01/2024 20:07:43 ABHA NO : NEW DELHI 110030 8800465156 **Test Report Status** <u>Final</u> Results Biological Reference Interval Units 2.4 g/dL GLOBULIN 2.0 - 4.0 Neonates -Pre Mature: 0.29 - 1.04 METHOD : CALCULATED PARAMETER

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM	136	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	4.68	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	100	98 - 107	mmol/L
METHOD : ISE INDIRECT			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Diaraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 14 Of 26







Units

REF. DOCTOR : SELF PATIENT NAME : NAMRATA KUMARI CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080XA008674 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NAMRF02038880 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 27/01/2024 10:18:25 DELHI ABHA NO REPORTED :28/01/2024 20:07:43 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval Final**

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy (adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

b>NOTE:
 b>NOTE:
 b>NOTE:
 b>NOTE:
 choose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.
 High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis. Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert

syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT

and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease,

Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)
 Lower than normal level may be due to:
 Myasthenia Gravis, Muscuophy
 URIC ACID, SERUM-
Couses of Increased levels:</br>
 Joint Intake, OCP, Multiple Sclerosis
 DM, Metabolic syndrome

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Deraraht

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 15 Of 26

View Details







PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080XA008674	AGE/SEX : 35 Years Female
	PATIENT ID : NAMRF02038880	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 27/01/2024 10:18:25
NEW DELHI 110030	ABHA NO :	REPORTED :28/01/2024 20:07:43
8800465156		

Test Repor	t Status	<u>Final</u>
------------	----------	--------------

Results

Biological Reference Interval Units

	CLINICAL PATH - URINALYSI	s	·····)		
MEDI WHEEL FULL BODY HEALTH	MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE				
PHYSICAL EXAMINATION, URINE					
COLOR	PALE YELLOW				
APPEARANCE	CLEAR				
CHEMICAL EXAMINATION, URIN	E				
РН	6.0	4.7 - 7.5			
METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD					
SPECIFIC GRAVITY	1.030	1.003 - 1.035			
METHOD : REFLECTANCE SPECTROPHOTOMETR	RY (PKA CHANGE OF PRETREATED POLY ELECTROLYTES)				
PROTEIN	NOT DETECTED	NOT DETECTED			
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PROTEIN-ERROR-OF-INDICATORS PRINCIPLE)					
GLUCOSE	NOT DETECTED	NOT DETECTED			
METHOD : REFLECTANCE SPECTROPHOTOMETR	<pre>{Y(GLUCOSE OXIDAE/PEROXIDASE METHOD)</pre>				
KETONES	NOT DETECTED	NOT DETECTED			

METHOD : REFLECTANCE SPECTROPHOTOMETRY(GLUCOSE OXID	AE/PEROXIDASE METHOD)	
KETONES	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (SODIUM NITRO	PRUSSIDE REACTION)	
BLOOD	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PEROXIDASE M	ETHOD)	
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION	DN)	
UROBILINOGEN	NORMAL	NORMAL
METHOD : REFLECTANCE SPECTROPHOTOMETRY - EHRLICH REAC	TION	
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION C	F NITRATE TO NITRITE	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	3-5	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	5-7	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			

Coracalit

Dr.Pranjali Vasisht LAB HEAD Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Page 16 Of 26

View Report

View Details







PATIENT NAME : NAMRATA KUMARI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080XA008674 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : NAMRF02038880 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 27/01/2024 10:18:25 DELHÍ REPORTED :28/01/2024 20:07:43 ABHA NO NEW DELHI 110030 : 8800465156 Biological Reference Interval **Test Report Status Final** Results Units

CASTS	NOT DETECTED	
CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION BACTERIA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED
YEAST	NOT DETECTED	NOT DETECTED

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind	
	of kidney impairment	
Glucose	Diabetes or kidney disease	
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst	
Urobilinogen	Liver disease such as hepatitis or cirrhosis	
Blood	Renal or genital disorders/trauma	
Bilirubin	Liver disease	
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary	
	tract infection and glomerular diseases	
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either	
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by	
	genital secretions	
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or	
	bladder catheters for prolonged periods of time	
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,	
	interaction with Bence-Jones protein	
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal	
	diseases	
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous	
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl	
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of	
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice	
Uric acid	arthritis	

Diaraht

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 17 Of 26

View Details







PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0080XA008674 PATIENT ID : NAMRF02038880 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :35 Years Female DRAWN : RECEIVED :27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43
Test Report Status <u>Final</u>	Results Biologica	Reference Interval Units

Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Coracalit

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Page 18 Of 26

X-30











PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0080XA008674 PATIENT ID : NAMRF02038880 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 35 Years Female DRAWN : RECEIVED : 27/01/2024 10:18:25 REPORTED : 28/01/2024 20:07:43
Test Report Status Final	Results Biological	Reference Interval Units

Coracalit

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 19 Of 26







PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0080XA008674 PATIENT ID : NAMRF02038880 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 35 Years Female DRAWN : RECEIVED : 27/01/2024 10:18:25 REPORTED : 28/01/2024 20:07:43
Test Report Status Final	Results Biological	Reference Interval Units

Coracalit

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



View Details

View Report

Page 20 Of 26

2630







5

PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO: 0080XA008674 PATIENT ID : NAMRF02038880 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :35 Years Female DRAWN : RECEIVED :27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

<u>Final</u>

Results

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE						
PAPANICOLAOU SMEAR						
TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY					
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED					
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY					
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.					
MICROSCOPY	PAP SMEARS STUDIED SHOW BENIGN SQUAMOUS SUPERFICIAL AND INTERMEDIATE CELLS ALONG WITH MONOLAYERED SHEETS OF BENIGN ENDOCERVICAL CELLS ON A MUCOID AND INFLAMMATORY BACKGROUND. THERE ARE PLENTY OF NEUTROPHILS, FEW OBSCURING THE CELL OUTLINES. NO EVIDENCE OF ATYPIA/MALIGNANCY SEEN					
ENDOMETRIAL CELLS (IN A WOMAN >/= 45 YRS)	ABSENT					

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Obraraht

Dr.Pranjali Vasisht LAB HEAD



DY. View Report

Page 21 Of 26

X-30

 \mathbf{z}



View Details

Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

PERFORMED AT :



PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0080XA008674 PATIENT ID : NAMRF02038880 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :35 Years Female DRAWN : RECEIVED :27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALELETTERREQUEST LETTERCX/12/24

ADDITIONAL COMMUNICATION

CX/12/24 REPEAT AFTER CONTROL OF INFLAMMATION

Chandni Garg

PERFORMED AT :

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD



View Details View Report

Page 22 Of 26

Kii 🗖

÷C,







PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080XA008674	AGE/SEX : 35 Years Female	
	PATIENT ID : NAMRF02038880	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 27/01/2024 10:18:25	
NEW DELHI 110030	ABHA NO :	REPORTED :28/01/2024 20:07:43	
8800465156			

Test Report Status Final

Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR

SAMPLE NOT RECEIVED



Dr.Ruby Jain Locum Microbilogist

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Dr. Nidhi Garg Lab Consultant





View Report

Page 23 Of 26







PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0080XA008674 PATIENT ID : NAMRF02038880	AGE/SEX : 35 Years Female DRAWN :		
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43		

Test Report Status Final

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE						
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE						
THYROID PANEL, SERUM						
T3 METHOD : COMPETITIVE (ECLIA)	111.70	80.00 - 200.00	ng/dL			
T4 METHOD : COMPETITIVE (ECLIA)	5.67	5.10 - 14.10	µg/dL			
TSH (ULTRASENSITIVE)	2.130	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Associa 1st Trimester 0.100 - 2.5 2nd Trimester 0.200 - 3.0 3rd Trimester 0.300 - 3.0	ition) 00 000			
METHOD : SANDWICH (ECLIA)						

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism

Drawht

Chandni Garg

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 24 Of 26

View Details



Test Report Status



AGE/SEX

DRAWN

REF. DOCTOR : SELF



Female

PATIENT NAME : NAMRATA KUMARI

CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156

<u>Final</u>

Results

CLIENT PATIENT ID:

PATIENT ID

ABHA NO

ACCESSION NO : 0080XA008674

:

: NAMRF02038880

Biological Reference Interval Units

:35 Years

RECEIVED : 27/01/2024 10:18:25

REPORTED :28/01/2024 20:07:43

:

4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
		_	_	_	(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

Deraraht

Dr.Pranjali Vasisht LAB HEAD

PERFORMED AT :

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



View Report

Page 25 Of 26

View Details







PATIENT NAME : NAMRATA KUMARI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : NAMRF02038880 CLIENT PATIENT ID:	AGE/SEX :35 Years Female DRAWN : RECEIVED :27/01/2024 10:18:25 REPORTED :28/01/2024 20:07:43		
Test Report Status Final	Results Biological	Reference Interval Units		

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
 Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Deraraht

Dr.Pranjali Vasisht LAB HEAD Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





View Report

Page 26 Of 26

View Details

